<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03248375</url>
  </required_header>
  <id_info>
    <org_study_id>GCO 15-0980</org_study_id>
    <nct_id>NCT03248375</nct_id>
  </id_info>
  <brief_title>Impact of Y90 Radiation Segmentectomy on HCC</brief_title>
  <official_title>The Impact of 90Yttrium (Y90) Radiation Segmentectomy on Hepatocellular Carcinoma and Cirrhosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Icahn School of Medicine at Mount Sinai</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Icahn School of Medicine at Mount Sinai</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>No</is_unapproved_device>
    <is_ppsd>No</is_ppsd>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this pilot study is to assess the efficacy of radiation segmentectomy with
      Theraspheres in patients with unresectable hepatocellular carcinoma that would qualify for
      thermal ablation as per the BCLC guidelines, but are unable to receive thermal ablation due
      to unfavorable location of target lesions.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 3, 2016</start_date>
  <completion_date type="Anticipated">July 31, 2020</completion_date>
  <primary_completion_date type="Anticipated">July 31, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Individuals with the targeted medical condition is given the experimental therapy and then followed over time to observe their response.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Tumor response according to mRECIST</measure>
    <time_frame>2 years</time_frame>
    <description>Efficacy of 90Yttrium (Y90) Radiation Segmentectomy on Unresectable Hepatocellular Carcinoma as measured by tumor response according to mRECIST.
CR = Disappearance of any intratumoral arterial enhancement in all target lesions PR = At least a 30% decrease in the sum of diameters of viable (enhancement in the arterial phase) target lesions, taking as reference the baseline sum of the diameters of target lesions SD = Any cases that do not qualify for either partial response or progressive disease PD = An increase of at least 20% in the sum of the diameters of viable (enhancing) target lesions, taking as reference the smallest sum of the diameters of viable (enhancing) target lesions recorded since treatment started</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to Progression (TTP)</measure>
    <time_frame>2 years</time_frame>
    <description>The length of time from Radiation Segmentectomy until progression of disease based on mRECIST</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Liver Function test</measure>
    <time_frame>2 years</time_frame>
    <description>Toxicity resulting from Radiation Segmentectomy with Theraspheres measured by liver function lab values</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of adverse events</measure>
    <time_frame>2 years</time_frame>
    <description>Number of adverse events according to the National Cancer Institute Common Terminology Criteria for Adverse Events v 4.0 (CTCAE).</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Hepatocellular Carcinoma</condition>
  <arm_group>
    <arm_group_label>Radiation Segmentectomy</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Radiation Segmentectomy on Resectable HCC</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Radiation Segmentectomy</intervention_name>
    <description>The administration of radioactivity in a branch of an artery of the liver</description>
    <arm_group_label>Radiation Segmentectomy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age greater than 18 years, regardless of race or gender

          -  Hepatocellular Carcinoma confirmed by histology for non-cirrhotic patients or
             non-invasive criteria according to AASLD for cirrhotic patients

          -  Child-Pugh class A or B7 without ascites

          -  Single tumor nodule ≤ 3 cm with a maximum distance of 5 mm from portal vein, hepatic
             vein, inferior vena cava, diaphragm, heart, stomach, bowel, liver capsule,
             gallbladder, bile duct

          -  No prior locoregional treatment or external beam therapy of current HCC (recurrent HCC
             after resection may be included)

          -  No confirmed extrahepatic metastases

          -  No evidence of macrovascular invasion

          -  ECOG 0

          -  Albumin &gt; 3.0 g/dL

          -  PLT ≥ 40 x103/μL

          -  WBC ≥ 1.5 x103/μL

          -  AST/ALT ≤ 5 times the upper limit of normal (U/L)

          -  Creatinine ≤ 2.0 mg /dL

          -  Alphafetoprotein (AFP) &lt; 200

          -  No indication for any possible curative treatment after multidisciplinary assessment
             (surgery, ablation)

          -  No contraindication to angiography or selective visceral catheterization

          -  No history of severe allergy or intolerance to contrast agents, narcotics, sedatives.

          -  Negative serum pregnancy test

          -  Signed informed consent form

        Exclusion Criteria:

          -  Not meeting the inclusion criteria
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Aaron Fischman, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Icahn School of Medicine at Mount Sinai</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ellen Weiss, BA, MA, MS</last_name>
    <phone>212-241-2317</phone>
    <email>ellen.weiss@mountsinai.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Edward Kim, MD</last_name>
    <phone>212-241-7409</phone>
    <email>edward.kim@mountsinai.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Icahn School of Medicine at Mount Sinai</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ellen Weiss, BA, MA, MS</last_name>
      <phone>212-241-2317</phone>
      <email>ellen.weiss@mountsinai.org</email>
    </contact>
    <contact_backup>
      <last_name>Edward Kim, MD</last_name>
      <phone>212-241-7409</phone>
      <email>edward.kim@mountsinai.org</email>
    </contact_backup>
    <investigator>
      <last_name>Aaron Fischman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Wong JB, McQuillan GM, McHutchison JG, Poynard T. Estimating future hepatitis C morbidity, mortality, and costs in the United States. Am J Public Health. 2000 Oct;90(10):1562-9.</citation>
    <PMID>11029989</PMID>
  </reference>
  <reference>
    <citation>Yao FY, Ferrell L, Bass NM, Watson JJ, Bacchetti P, Venook A, Ascher NL, Roberts JP. Liver transplantation for hepatocellular carcinoma: expansion of the tumor size limits does not adversely impact survival. Hepatology. 2001 Jun;33(6):1394-403.</citation>
    <PMID>11391528</PMID>
  </reference>
  <reference>
    <citation>Llovet JM, Mas X, Aponte JJ, Fuster J, Navasa M, Christensen E, Rodés J, Bruix J. Cost effectiveness of adjuvant therapy for hepatocellular carcinoma during the waiting list for liver transplantation. Gut. 2002 Jan;50(1):123-8.</citation>
    <PMID>11772979</PMID>
  </reference>
  <reference>
    <citation>Llovet JM, Bruix J. Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survival. Hepatology. 2003 Feb;37(2):429-42. Review.</citation>
    <PMID>12540794</PMID>
  </reference>
  <reference>
    <citation>Curley SA, Izzo F, Ellis LM, Nicolas Vauthey J, Vallone P. Radiofrequency ablation of hepatocellular cancer in 110 patients with cirrhosis. Ann Surg. 2000 Sep;232(3):381-91.</citation>
    <PMID>10973388</PMID>
  </reference>
  <reference>
    <citation>Cheng JC, Wu JK, Lee PC, Liu HS, Jian JJ, Lin YM, Sung JL, Jan GJ. Biologic susceptibility of hepatocellular carcinoma patients treated with radiotherapy to radiation-induced liver disease. Int J Radiat Oncol Biol Phys. 2004 Dec 1;60(5):1502-9.</citation>
    <PMID>15590181</PMID>
  </reference>
  <reference>
    <citation>Dawson LA, Ten Haken RK. Partial volume tolerance of the liver to radiation. Semin Radiat Oncol. 2005 Oct;15(4):279-83. Review.</citation>
    <PMID>16183482</PMID>
  </reference>
  <reference>
    <citation>Gaba RC, Lewandowski RJ, Kulik LM, Riaz A, Ibrahim SM, Mulcahy MF, Ryu RK, Sato KT, Gates V, Abecassis MM, Omary RA, Baker TB, Salem R. Radiation lobectomy: preliminary findings of hepatic volumetric response to lobar yttrium-90 radioembolization. Ann Surg Oncol. 2009 Jun;16(6):1587-96. doi: 10.1245/s10434-009-0454-0. Epub 2009 Apr 9.</citation>
    <PMID>19357924</PMID>
  </reference>
  <reference>
    <citation>Young JY, Rhee TK, Atassi B, Gates VL, Kulik L, Mulcahy MF, Larson AC, Ryu RK, Sato KT, Lewandowski RJ, Omary RA, Salem R. Radiation dose limits and liver toxicities resulting from multiple yttrium-90 radioembolization treatments for hepatocellular carcinoma. J Vasc Interv Radiol. 2007 Nov;18(11):1375-82.</citation>
    <PMID>18003987</PMID>
  </reference>
  <reference>
    <citation>Riaz A, Lewandowski RJ, Kulik LM, Mulcahy MF, Sato KT, Ryu RK, Omary RA, Salem R. Complications following radioembolization with yttrium-90 microspheres: a comprehensive literature review. J Vasc Interv Radiol. 2009 Sep;20(9):1121-30; quiz 1131. doi: 10.1016/j.jvir.2009.05.030. Epub 2009 Jul 29. Review.</citation>
    <PMID>19640737</PMID>
  </reference>
  <reference>
    <citation>Lencioni R, Llovet JM. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis. 2010 Feb;30(1):52-60. doi: 10.1055/s-0030-1247132. Epub 2010 Feb 19. Review.</citation>
    <PMID>20175033</PMID>
  </reference>
  <reference>
    <citation>Riaz A, Gates VL, Atassi B, Lewandowski RJ, Mulcahy MF, Ryu RK, Sato KT, Baker T, Kulik L, Gupta R, Abecassis M, Benson AB 3rd, Omary R, Millender L, Kennedy A, Salem R. Radiation segmentectomy: a novel approach to increase safety and efficacy of radioembolization. Int J Radiat Oncol Biol Phys. 2011 Jan 1;79(1):163-71. doi: 10.1016/j.ijrobp.2009.10.062. Epub 2010 Apr 24.</citation>
    <PMID>20421150</PMID>
  </reference>
  <reference>
    <citation>Bargellini I, Bozzi E, Campani D, Carrai P, De Simone P, Pollina L, Cioni R, Filipponi F, Bartolozzi C. Modified RECIST to assess tumor response after transarterial chemoembolization of hepatocellular carcinoma: CT-pathologic correlation in 178 liver explants. Eur J Radiol. 2013 May;82(5):e212-8. doi: 10.1016/j.ejrad.2012.12.009. Epub 2013 Jan 15.</citation>
    <PMID>23332890</PMID>
  </reference>
  <reference>
    <citation>Komorizono Y, Oketani M, Sako K, Yamasaki N, Shibatou T, Maeda M, Kohara K, Shigenobu S, Ishibashi K, Arima T. Risk factors for local recurrence of small hepatocellular carcinoma tumors after a single session, single application of percutaneous radiofrequency ablation. Cancer. 2003 Mar 1;97(5):1253-62.</citation>
    <PMID>12599233</PMID>
  </reference>
  <reference>
    <citation>Golfieri R, Renzulli M, Mosconi C, Forlani L, Giampalma E, Piscaglia F, Trevisani F, Bolondi L; Bologna Liver Oncology Group (BLOG). Hepatocellular carcinoma responding to superselective transarterial chemoembolization: an issue of nodule dimension? J Vasc Interv Radiol. 2013 Apr;24(4):509-17. doi: 10.1016/j.jvir.2012.12.013. Epub 2013 Feb 18.</citation>
    <PMID>23428355</PMID>
  </reference>
  <verification_date>August 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 10, 2017</study_first_submitted>
  <study_first_submitted_qc>August 10, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">August 14, 2017</study_first_posted>
  <last_update_submitted>August 10, 2017</last_update_submitted>
  <last_update_submitted_qc>August 10, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 14, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Icahn School of Medicine at Mount Sinai</investigator_affiliation>
    <investigator_full_name>Aaron M fischman</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <keyword>Unresectable Hepatocellular Carcinoma</keyword>
  <keyword>Radioembolization</keyword>
  <keyword>Radiation Segmentectomy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

